Tower Research Capital (TRC)’s NewAmsterdam Pharma NAMS Stock Holding History
Bought
Maintained
Sold
Other funds holding NAMS
DFO
Tower Research Capital (TRC)'s NAMS Position: Q3 2026 in Review
Tower Research Capital (TRC) increased its NewAmsterdam Pharma (NAMS) stake by 192% in Q3 2026, buying an estimated $238K and bringing the position to 13,119 shares worth $319K. The position accounts for ﹤0.01% of the portfolio, ranked #2045.
Tower Research Capital (TRC) first reported a position in NAMS in Q4 2022 and has held it in 10 quarters since. 183 funds tracked by Wall St. Rank hold NAMS as of Q3 2026.
- Tower Research Capital (TRC) held 13,119 shares of NewAmsterdam Pharma worth $319K as of Q3 2026.
- Tower Research Capital (TRC) bought 8,619 NewAmsterdam Pharma shares in Q3 2026, an estimated $238K.
- NewAmsterdam Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #2045 holding.
- Tower Research Capital (TRC) first reported a position in NewAmsterdam Pharma in Q4 2022 and has held it in 10 quarters since.
- 183 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.